What were the key takeaways from Pelthos Therapeutics's earnings call?

What factors drove the changes in Pelthos Therapeutics's revenue and profit?

What is the market's earnings forecast for Pelthos Therapeutics next quarter?

What were the key takeaways from Pelthos Therapeutics’s earnings call?

What does Pelthos Therapeutics do and what are its main business segments?

What is Pelthos Therapeutics's gross profit margin?

What is Pelthos Therapeutics's latest dividend and current dividend yield?

What guidance did Pelthos Therapeutics's management provide for the next earnings period?

- **ZELSUVMI launch success**: $7.1M Q3 revenue, 41% month-over-month growth in October prescriptions.
- **Sales force expansion**: Adding 14 reps to cover major cities, targeting 64 reps by Q1 2026.
- **Xepi acquisition**: $18M convertible notes financing to accelerate launch of complementary impetigo treatment.
- **Financial targets**: Cash flow breakeven by end-2026, $175M peak ZELSUVMI revenue by 2028.
- **Market dynamics**: No seasonal trends, but holiday-related office closures may impact Q4 growth.

**【CEO Opening Remarks】**
- Announced successful acquisition of Pelthos business, NYSE listing, and $50M PIPE financing to support ZELSUVMI launch.
- Launched ZELSUVMI, the first FDA-approved at-home treatment for molluscum contagiosum (MC), generating $7.1M in Q3 net product revenue.
- Acquired Xepi, a topical treatment for impetigo, with $18M convertible notes financing to accelerate commercialization.
- Projected cash flow breakeven by end of 2026, targeting $175M peak revenue for ZELSUVMI by 2028.

**【Sai Rangarao - ZELSUVMI Launch Metrics】**
- Q3 shipments: 4,900 units to wholesalers, 3,000 to pharmacies; 2,716 prescriptions from 1,169 unique prescribers.
- October prescriptions up 41% YoM, with 516 units dispensed in last week of Q3 (annualized $52M run rate).
- GTN rate 25.3% in Q3, expected to rise to mid-30% by Q1 2026.
- Expanded sales force from 50 to 64 reps by mid-January to cover major metropolitan areas.

**【Frank Knuettel - Financial Highlights】**
- Q3 2025: $7.1M net product revenue, $16.2M GAAP net loss, $1.83 EPS (as-converted basis).
- COGS $2.3M (includes inventory step-up costs); normalized COGS expected by mid-2026.
- SG&A expenses $19.6M (includes $3.2M non-cash charges, $1M one-time merger costs).
- $14.2M cash on hand, $8M A/R; $18M convertible notes financing closed in Q3.

**【Q&A Highlights】**
- **Prescriber behavior**: 60% of HCPs wrote 1 script, 40% wrote 2+; 3 HCPs wrote 22-27 scripts.
- **Holiday impact**: Acute treatment requires in-office prescription, expect softening in Q4.
- **Refill rates**: 1.2 units per patient average; 3 units needed for full 12-week course.
- **Sales force profitability**: All 50 reps covered costs within 9 weeks; new 14 reps expected to breakeven quickly.
- **Price strategy**: No commercial contracts, cautious about future price increases.
- **Pipeline**: Evaluating additional NitroCil-based products; no immediate plans for new acquisitions beyond Xepi.

PTHS

PTHS fundamentals

Earnings Call

You can ask Aime